Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Sales and Divestitures (2020 - 2022)

Mirum Pharmaceuticals (MIRM) has 3 years of Gains from Sales and Divestitures data on record, last reported at $122464.0 in Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures fell 8.33% year-over-year to $122464.0; the TTM value through Dec 2022 reached $122464.0, down 8.33%, while the annual FY2022 figure was $122464.0, 8.33% down from the prior year.
  • Gains from Sales and Divestitures reached $122464.0 in Q4 2022 per MIRM's latest filing, up from $33398.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $133593.0 in Q4 2020 and bottomed at $33396.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 3 years is $68651.8, with a median of $50098.0 recorded in 2020.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 199.99% in 2021, then tumbled 66.67% in 2022.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $133593.0 in 2020, then changed by 0.0% to $133593.0 in 2021, then fell by 8.33% to $122464.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $122464.0 in Q4 2022, $33398.0 in Q3 2022, and $66796.0 in Q2 2022.